Patents Issued in March 20, 2007
-
Patent number: 7192908Abstract: An aqueous oilfield treatment fluid containing a chelating agent and an HF source is described. This fluid is effective at dissolving siliceous materials such as clays and keeping the dissolved materials in solution. In particular it is effective at preventing re-precipitation of initially-dissolved silicon as silica and therefore reduces damage to sandstones with which it is contacted. Methods are given for using this fluid for sandstone matrix stimulation, removal of clay-containing drilling fluid components and filter cakes from wellbores, sandstone acid fracturing, and gravel pack and proppant pack cleaning.Type: GrantFiled: April 21, 2003Date of Patent: March 20, 2007Assignee: Schlumberger Technology CorporationInventors: Wayne Frenier, Murtaza Ziauddin, Stephen Davies, Frank Chang
-
Patent number: 7192909Abstract: The invention relates to the use of polyolefin waxes as external lubricants and release agents for plastics. Said polyolefin waxes are produced by using metallocene catalysts, whereby the polyolefin waxes are homopolymerizates of ethylene or are copolymerizates of ethylene with one or more 1-olefins, and linear or branched, substituted or non-substituted olefins having 3–18 C atoms are used as 1-olefins. The processable plastic mixtures produced in this manner have a distinctively longer tack-free time and exhibit an improved behavior with regard to mold release.Type: GrantFiled: March 14, 2001Date of Patent: March 20, 2007Assignee: Clariant Produkte (Deutschland) GmbHInventors: Eric Richter, Harald Kiesel
-
Patent number: 7192910Abstract: Composition for cleaning or etching a semiconductor substrate and method for using the same. The composition may include a fluorine-containing compound as an active agent such as a quaternary ammonium fluoride, a quaternary phosphonium fluoride, sulfonium fluoride, more generally an -onium fluoride or “multi” quaternary -onium fluoride that includes two or more quaternary- onium groups linked together by one or more carbon-containing groups. The composition may further include a pH adjusting acid such as a mineral acid, carboxylic acid, dicarboxylic acid, sulfonic acid, or combination thereof to give a pH of about 2 to 9. The composition can be anhydrous and may further include an organic solvent such as an alcohol, amide, ether, or combination thereof. The composition are useful for obtaining improved etch rate, etch selectivity, etch uniformity and cleaning criteria on a variety of substrates.Type: GrantFiled: October 27, 2004Date of Patent: March 20, 2007Assignee: Sachem, Inc.Inventors: William A. Wojtczak, Dean Dewulf, Sian Collins
-
Patent number: 7192911Abstract: A machine dishwasher product comprising: a) 1 to 60% by weight of nonaqueous solvent(s), b) 0.1 to 70% by weight of copolymers of i) unsaturated carboxylic acids ii) monomers containing sulfonic acid groups iii) optionally further ionic or nonionogenic monomers c) 5 to 30% by weight of nonionic surfactant(s). Also, the machine dishwasher product, packaged in portions in a water-soluble enclosure.Type: GrantFiled: January 7, 2004Date of Patent: March 20, 2007Assignee: Henkel KGaAInventors: Matthias Sunder, Rolf Bayersdoerfer, Christian Nitsch, Bernd Richter, Arnd Kessler, Michael Dreja, Sven Mueller
-
Patent number: 7192912Abstract: A solvent blend effective to remove grease and oil includes a hydro treated light petroleum distillate in combination with a glycol ether and an ester solvent. Each of the components has a vapor pressure of less than 0.1 mm Hg at 20° C. and accordingly contained no volatile organic compounds. These effectively remove grease and oil and can be emulsified into water to form an aqueous cleaning composition.Type: GrantFiled: March 18, 2004Date of Patent: March 20, 2007Assignee: JohnsonDiversey, Inc.Inventor: Benjamin Laux
-
Patent number: 7192913Abstract: A composition having a fragrance that substantially mimics a fragrance of a plant is made by (a) identifying a plurality of different chemical entities emitted from a plant, wherein the plurality of different chemical entities combine to form the fragrance of the plant; (b) determining a concentration of the plurality of different chemical entities emitted from the plant, the plurality of different chemical entities including at least a first chemical entity and a second chemical entity, the first and second chemical entities having different chemical structures; (c) providing a stock of the first chemical entity and a stock of the second chemical entity; and (d) mixing together aliquots of the stock of the first chemical entity and the stock of the second chemical entity to form a mixture wherein a ratio of the concentration of the first chemical entity to second chemical entity is substantially the same as that emitted from the plant.Type: GrantFiled: February 13, 2004Date of Patent: March 20, 2007Assignee: University of Florida Research Foundation, Inc.Inventors: David G. Clark, Kenichi Shibuya
-
Patent number: 7192914Abstract: This invention provides methods and compositions for treating and preventing atherosclerosis other undesired blood clotting. The methods for treating and preventing atherosclerosis and related conditions involve administering to a mammal an agent that reduces activity of an ST3Gal IV sialyltransferase, which results in enhanced clearance of von Willebrand Factor (vWF) from the mammal.Type: GrantFiled: September 27, 2000Date of Patent: March 20, 2007Assignee: The Regents of the University of CaliforniaInventors: Jamey D. Marth, Lesley G. Ellies
-
Patent number: 7192915Abstract: Disclosed is the characterization and purification of DNA encoding polypeptides useful for the stimulation of glial cell mitogenesis. Methods for the synthesis, purification and testing of both known and novel polypeptides for their use as both therapeutic and diagnostic aids in the treatment of diseases involving glial cells are also provided. Methods are also provided for the use of these polypeptides in the prevention or treatment of multiple sclerosis.Type: GrantFiled: October 22, 1996Date of Patent: March 20, 2007Assignees: Acorda Therapeutics, Inc., Ludwig Institute for Cancer ResearchInventors: Andrew Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchioni, Mario Su Chen, Ian Hiles
-
Patent number: 7192916Abstract: This invention provides isolated nucleic acids encoding a motor neuron restricted MNR2 protein, and a homeobox HB9 protein. Also provided are purified MNR2 and HB9 proteins, antibodies recognizing these proteins, transgenic animals expressing these proteins, and functionally equivalent analogs of these proteins. Finally, methods are disclosed for inducing differentiation of somatic motor neurons, and for treating diseases related to the lack of normally functioning motor neurons, neurodegenerative diseases, acute nervous system injury, and neuromuscular disease.Type: GrantFiled: March 29, 2001Date of Patent: March 20, 2007Assignee: The Trustees of Columbia University in the City of New YorkInventors: Thomas M. Jessell, Yasuto Tanabe, Christopher William
-
Patent number: 7192917Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including, septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.Type: GrantFiled: November 21, 2003Date of Patent: March 20, 2007Assignee: The Feinstein Institute for Medical ResearchInventors: Kevin J. Tracey, Haichao Wang
-
Patent number: 7192918Abstract: Tripeptide and tetrapeptide sulfones, pharmaceutical compositions containing them, their pharmaceutical use, and their preparation, are disclosed. The compounds are useful in potentiating the cytotoxic effects of chemotherapeutic agents in tumor cells, selectively exerting toxicity in tumor cells, elevating the production of GM progenitors in bone marrow cells, stimulating the differentiation of bone marrow, mitigating the myelosuppressive effects of chemotherapeutic agents, and modulating hematopoiesis in bone marrow.Type: GrantFiled: January 5, 2006Date of Patent: March 20, 2007Assignee: Telik, Inc.Inventors: Steven R. Schow, Natalia Aurrecoechea
-
Patent number: 7192919Abstract: The present invention provides sustained release compositions that can be manufactured easily while providing long duration of the pharmaceutically useful protein being delivered. The compositions comprise insoluble complexes of the pharmaceutically useful protein and a precipitating agent at an appropriate ratio to achieve a desired sustained release profile. The precipitating agent can be selected from a group of various agents including divalent metal cations, Hofmeister series salts and pH adjusters. Particularly provided are compositions comprising insulin that are suitable for pulmonary delivery.Type: GrantFiled: January 7, 2005Date of Patent: March 20, 2007Inventors: Stelios Tzannis, Nancy Dasovich, Sandeep Kumar, Negar Sadrzadeh
-
Patent number: 7192920Abstract: A subject of the invention, in all possible isomer forms as well as their mixtures, is the compounds of formula (I): in which either R1: H or CH3 and R2: cyclohexyl substituted by an amine, a (CH2)b-C?N radical or R1 and R2 together with the nitrogen which carries them form a ring with 3, 4 or 5 carbons optionally substituted by an amine R3: hydrogen, methyl or hydroxyl R4: hydrogen or hydroxyl R: represents a linear, branched or cyclic chain T: hydrogen, methyl, CH2CONH2, CH2C?N, a (CH2)2NH2 or (CH2)2Nalk+X? radical, X halogen and alk alkyl Y: hydrogen, hydroxyl, halogen or OSO3H, W: H or OH, Z: H, CH3. The compounds of formula (I) have antifungal properties.Type: GrantFiled: September 13, 2005Date of Patent: March 20, 2007Assignee: Aventis Pharma SAInventors: Patrick Fauveau, Stephen Hawser, Gilles Lebourg, Laurent Schio
-
Patent number: 7192921Abstract: The present invention provides a conjugate containing a moiety linked to a homing molecule that selectively homes to tumor lymphatic vasculature. The invention also provides a method of directing a moiety to tumor lymphatic vasculature in a subject by administering to the subject a conjugate containing a moiety linked to a homing molecule that selectively homes to tumor lymphatic vasculature.Type: GrantFiled: November 5, 2002Date of Patent: March 20, 2007Assignee: The Burnham InstituteInventors: Pirjo Laakkonen, Kimmo Porkka, Jason A. Hoffman, Erkki Ruoslahti
-
Patent number: 7192922Abstract: A method of treating a patient having heart failure due to LV systolic dysfunction with an LV ejection fraction less than 40%. The method includes the steps of administering to a patient in need thereof, a compound selected from the group consisting of GIP, GIP analogs, GIP derivatives and pharmaceutically-acceptable salts thereof, GLP-1, GLP-1 analogs, GLP-1 derivatives and pharmaceutically-acceptable salts thereof, at a therapeutically effective amount to improve LV function.Type: GrantFiled: November 19, 2002Date of Patent: March 20, 2007Assignee: Allegheny-Singer Research InstituteInventors: Richard P. Shannon, Dariush Elahi
-
Patent number: 7192923Abstract: Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.Type: GrantFiled: December 11, 2002Date of Patent: March 20, 2007Assignee: The Procter & Gamble CompanyInventors: Robert Joseph Isfort, Wieslaw Adam Mazur
-
Patent number: 7192924Abstract: Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.Type: GrantFiled: December 11, 2002Date of Patent: March 20, 2007Assignee: The Procter & Gamble CompanyInventors: Robert Joseph Isfort, Wieslaw Adam Mazur
-
Patent number: 7192925Abstract: The present invention provides isoformes from a peptide family belonging to South American scorpion Tityus serrulatus that acts as hypotensive agents by potentiating Bradykinin and, therefore, can be used as anti-hypertensive drugs. A peptide was firstly isolated from Tityus serrulatus venom and showed a strong and long-lasted hypotensive activity when tested in rats. This peptide was first named TsHpt-I (Tityus serrulatus Hypotensin-I). Also, three more highly similar isoformes were identified and revealed a peptide family with very close primary structure. They were named TsHpt-II, TsHpt-III and TsHpt-IV.Type: GrantFiled: June 9, 2003Date of Patent: March 20, 2007Assignee: Universidade Federal de Minas GeraisInventors: Maria Elena de Lima Perez-Garcia, Carlos Ribeiro Diniz, Robson Augusto Souza Dos Santos, Pierre Edouard Bougis, Marie-France Eauclaire, Adriano Monteiro de Castro Pimenta
-
Patent number: 7192926Abstract: The invention relates to compositions suitable for plasma substitution comprising as a plasma expander a recombinant gelatin-like protein. Characteristic is that the gelatin-like protein can be a monomer or a polymer like a dimer, trimer or a tetramer of a human recombinant gelatin-like protein having an isolectric point of less than 8. The resulting gelatin-like proteins provide a method to control the clearance rate of a plasma expander by its molecular weight. Preferably the gelatin-like proteins have a low hydroxyproline content which prevents the composition from gelling and thus allows the use of high-molecular weight proteins in order to establish a suitable colloid osmotic pressure. An additional advantage of the gelatin-like proteins is that these avoid the risk of anaphylactic shock that exists in conjunction with the use of commercially available preparations.Type: GrantFiled: September 10, 2003Date of Patent: March 20, 2007Assignee: Fuji Photo Film B.V.Inventors: Jan Bastiaan Bouwstra, Yuzo Toda
-
Patent number: 7192927Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the invention are also described.Type: GrantFiled: February 12, 2004Date of Patent: March 20, 2007Assignee: Gemvax ASInventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Moller, Marianne Klemp Gjertsen, Ingvil Saeterdal
-
Patent number: 7192928Abstract: The present invention provides peptides which affect T-cells, presumably by action on the T-cell antigen receptor. The present invention further relates to the therapy of various inflammatory and autoimmune disease states involving the use of these peptides. Specifically, the peptides are useful in the treatment of disorders where T-cells are involved or recruited. In one aspect the peptides have the formula: R1-A—B—A—R2 in which A is a hydrophobic amino acid or a hydrophobic peptide sequence comprising between 2 and 10 amino acids; B is a charged amino acid; R1 is NH2 and R2 is COOH. In another aspect the peptides have the formula: R1-A—B—C—R2 in which A is a peptide sequence of between 0 and 5 amino acids; B is cysteine; C is a peptide sequence of between 2 to 10 amino acids; R1 is NH2; and R2 is COOH.Type: GrantFiled: June 11, 1997Date of Patent: March 20, 2007Assignee: Northern Sydney & Central Coast Area Health ServicesInventor: Nicholas Manolios
-
Patent number: 7192929Abstract: The present invention is directed to methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using compounds containing or based on peptides comprising a part of the amino acid sequence of a neural thread protein.Type: GrantFiled: July 19, 2002Date of Patent: March 20, 2007Assignee: Nymox CorporationInventor: Paul Averback
-
Patent number: 7192930Abstract: Method and peptide for regulating cellular activity includes a panel of synthesized peptides that have biological effects on inhibiting or enhancing cellular activity. Selected peptides can be used as therapy to reduce and/or inhibit, or initiate and/or enhance, an inflammatory response in a subject.Type: GrantFiled: July 12, 2005Date of Patent: March 20, 2007Assignees: U.S. Department of Veterans Affairs, Oregon Health & Science UniversityInventors: Steven H. Hefeneider, Sharon L. McCoy
-
Patent number: 7192931Abstract: This invention relates to methods for the treatment or prevention of central nervous system (CNS) cell damage and functional damage in mammals due to demyelinating disease including multiple sclerosis. More specifically, the invention comprises a method of treating a demyelinating disease of the CNS in a mammal, the method comprising co-administering to the mammal, either sequentially or simultaneously, GPE or analogues or peptidomimetics or a prodrug thereof, or a pharmaceutically acceptable salt thereof, and an AMPA (?-amino-3-hydroxy-5-methyl-4-isoxazolepropionate)/kainate antagonist, or a pharmaceutically acceptable salt thereof, and an anti-inflammatory agent.Type: GrantFiled: October 11, 2001Date of Patent: March 20, 2007Assignee: Neuren Pharmaceuticals Ltd.Inventors: Geoffrey Wayne Krissansen, Jagat Rakesh Kanwar
-
Patent number: 7192932Abstract: Pharmaceutical compositions useful for treating immunosuppressive disease and containing compounds capable of inhibiting cAMP-dependent protein kinase A (PKA) as well as use of the same, are described.Type: GrantFiled: October 28, 1999Date of Patent: March 20, 2007Assignee: Lauras ASInventors: Kjetil Taskén, Einar M. Aandahl, Pål Aukrust, Bjørn S. Skålhegg, Fredrik Müller, Stig Frøland, Vidar Hansson
-
Patent number: 7192933Abstract: Disclosed is a method of expressing an exogenous gene in a mammalian cell, involving infecting the cell with a baculovirus whose genome carries an exogenous gene, and growing the cell under conditions such that the gene is expressed. Also disclosed is a method of treating a gene deficiency disorder in a mammal by providing to a cell a therapeutically effective amount of a baculovirus whose genome carries an exogenous gene and growing the cell under conditions such that the exogenous gene is expressed in the mammal.Type: GrantFiled: November 19, 1996Date of Patent: March 20, 2007Assignee: The Massachusetts General HospitalInventor: Frederick M. Boyce
-
Patent number: 7192934Abstract: The present invention relates to novel methods and compositions for blocking transmission of Plasmodium vivax which cause malaria. In particular, Pvs25 and Pvs28 polypeptides, variants, including deglycosylated forms, and fusion proteins thereof, are disclosed which, when administered to a susceptible organism, induce an immune response against a 25 kD and 28 kD protein, respectively, on the surface of Plasmodium vivax zygotes and ookinetes. This immune response in the susceptible organism can block transmission of malaria.Type: GrantFiled: December 4, 1998Date of Patent: March 20, 2007Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: David C. Kaslow, Takafumi Tsuboi, Motomi Torii
-
Patent number: 7192935Abstract: Nucleic acid sequences which encode biologically active ETF, expression vectors which direct the expression of ETF, ETF polypeptides, antibodies which specifically bind ETF and processes for preparing the same are disclosed. Also disclosed are methods for treating or preventing gastrointestinal diseases and HIV or HIV-associated diseases.Type: GrantFiled: November 28, 2000Date of Patent: March 20, 2007Assignee: Amgen Inc.Inventors: Kenneth H. Grabstein, Dirk M. Anderson, June R. Eisenman, Victor Fung, Charles Rauch
-
Patent number: 7192936Abstract: 2? and/or 3? prodrugs of 1?, 2?, 3? or 4?-branchednucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.Type: GrantFiled: December 6, 2004Date of Patent: March 20, 2007Assignees: Idenix Pharmaceuticals, Inc., Centre National de la Recherche Scientifique, Universita Degli Studi Di CagliariInventors: Paola LaColla, Richard Storer, Gilles Gosselin, Jean-Pierre Sommadossi
-
Patent number: 7192937Abstract: The use of compositions containing one or more oligosaccharides in an amount effective to disinfect and/or preserve medical devices, pharmaceutical preparations, and the like is described. Buffered solutions containing one or more oligosaccharide-containing compositions and methods of making and using the same are also described.Type: GrantFiled: May 19, 2004Date of Patent: March 20, 2007Assignee: Bausch & Lomb IncorporatedInventor: Erning Xia
-
Patent number: 7192938Abstract: The present invention refers to a pharmaceutical composition of a bisphosphonic acid or salt thereof, and an excipient thereof, and a method of treating disorder characterized by pathologically increased bone resorption comprising orally administering at least 150% of the expected efficious daily dose of a bisphosphonic acid or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients thereof and administering the dose at a period of one two or three consecutive days per month.Type: GrantFiled: November 29, 2004Date of Patent: March 20, 2007Assignee: Hoffmann-La Roche Inc.Inventors: Frieder Bauss, Bernhard Pichler, Stephen Turley
-
Patent number: 7192939Abstract: The present invention relates to the novel isolated 12–30 strain of Pestalotiopsis microspora capable of producing novel antioxidant and antimycotic agents. The present invention also relates to the novel isolated 3,5,7 trisubstituted isobenzofuranone and derivatives thereof, methods of isolating the novel isobenzofuranone from cultures P. microspora 12–30, and to novel uses of the compound as an antioxidant and antimycotic agent. The present invention further relates to a novel 1,5,7 trisubstituted 1,3-dihydroisobenzofuran and derivatives thereof, methods of isolating this novel compound from cultures of Pestalotiopsis microspora 12–30, and to uses thereof.Type: GrantFiled: January 30, 2003Date of Patent: March 20, 2007Assignee: Montana State UniversityInventors: Gary Strobel, Eugene Ford, James K. Harper
-
Patent number: 7192940Abstract: The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.Type: GrantFiled: July 16, 2004Date of Patent: March 20, 2007Assignee: Esperion Therapeutics, Inc.Inventors: Jean-Louis Henri Dasseux, Carmen Daniela Oniciu
-
Patent number: 7192941Abstract: Methods are provided for the treatment of pulmonary hypertension and other conditions associated therewith. In particular, the methods include treatment of pulmonary hypertension with estradiol metabolite or estradiol metabolite associated with biodegradable microparticles or nanoparticles alone or in combination with another therapeutic agent. Preferred estradiol metabolites include 2-methoxyestradiol, 4-methoxyestradiol, 2-hydroxyestradiol, and 4-hydroxyestradiol, and/or to synthetic derivatives and analogues thereof or prodrugs thereof. The compositions may also be in the form of a controlled release formulation.Type: GrantFiled: February 20, 2004Date of Patent: March 20, 2007Assignee: University of PittsburghInventors: Stevan P. Tofovic, Edwin K. Jackson
-
Patent number: 7192942Abstract: The process for making crystals of a 11 ?-benzaldoxim-estra-4,9-diene derivative having an average particle size of from 3 ?m to 25 ?m and a maximum particle size of 100 ?m, includes subjecting a supersaturated solution containing a special 11?-benzaldoxim-estra-4,9-diene derivative of formula (I) to a wet milling by a wet milling apparatus while crystallizing, In order to obtain a primary particle suspension. Crystals obtained according to this process and pharmaceutical preparations containing them are also described and are part of the invention.Type: GrantFiled: April 17, 2003Date of Patent: March 20, 2007Assignee: Schering AGInventors: Detlef Grawe, Hagen Gerecke, Peter Hoesel, Annette Eichardt, Sabine Gliesing, Uwe Mueller
-
Patent number: 7192943Abstract: The present invention relates to a compound of the formula [I]: wherein R1 is lower alkyl or hydroxy(lower)alkyl, and R2 is hydrogen or amino protecting group, or R1 and R2 are bonded together and form lower alkylene; R is -A-R6 wherein A is bond, —NHCO—(CH2CO)n—, lower alkylene, —NH—CO—CO— or the like, and R6 is wherein R7, R8, R9 and R10 are independently amino, guanidino, amidino or the like; R4 is carboxy or protected carboxy; and R5 is amino or protected amino, or a pharmaceutically acceptable salt thereof, a process for preparing a compound of the formula [I], and a pharmaceutical composition comprising a compound of the formula [I] in admixture with a pharmaceutically acceptable carrier.Type: GrantFiled: September 17, 2004Date of Patent: March 20, 2007Assignees: Astellas Pharma Inc., Wakunaga Pharmaceutical Co., Ltd.Inventors: Toshio Yamanaka, Kenji Murano, Ayako Toda, Hidenori Ohki, Masaru Oogaki, Shinya Okuda, Kohji Kawabata, Satoshi Inoue, Keiji Misumi, Kenji Itoh, Kenji Sato
-
Patent number: 7192944Abstract: The present invention provides compounds represented by the structural formula (I): or pharmaceutically acceptable isomers, salts, solvates or esters of the compound of Formula (I), wherein each of the substituents is as specified herein, formulations including the above compounds, processes for preparing the same and methods for treating vascular conditions, such as atherosclerosis or hypercholesterolemia, diabetes, obesity, stroke, demyelination and lowering plasma levels of sterols and/or stanols.Type: GrantFiled: March 3, 2004Date of Patent: March 20, 2007Assignee: Schering Corp.Inventors: Duane A. Burnett, John W. Clader
-
Patent number: 7192945Abstract: The present invention relates to compounds of the formula (I): (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia.Type: GrantFiled: December 17, 2001Date of Patent: March 20, 2007Assignee: AstraZeneca ABInventors: Ingemar Starke, Mikael Dahlstrom, David Blomberg
-
Patent number: 7192946Abstract: The present invention relates to compounds of formula (I), wherein variable groups are as defined within; pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia.Type: GrantFiled: August 30, 2002Date of Patent: March 20, 2007Assignee: AstraZeneca ABInventors: Ingemar Starke, Mikael Ulf Johan Dahlstrom, David Blomberg, Suzanne Alenfalk, Peter Nordberg, Andreas Christer Wallberg, Stig Jonas Bostrom
-
Patent number: 7192947Abstract: The present invention relates to compounds of formula (I): (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia.Type: GrantFiled: June 10, 2003Date of Patent: March 20, 2007Assignee: AstraZeneca ABInventors: Ingemar Starke, Mikael Ulf Johan Dahlstrom, Suzanne Alenfalk, Tore Skjaret, Malin Lemurell
-
Patent number: 7192948Abstract: The invention encompasses a series cyclic bicyclic heterocyclic compounds of Formula I which are inhibitors of HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS.Type: GrantFiled: May 26, 2005Date of Patent: March 20, 2007Assignee: Bristol-Myers Squibb CompanyInventors: Jacques Banville, Gilles Bouthillier, B. Narasimhulu Naidu, Roger Remillard, Michael A. Walker
-
Patent number: 7192949Abstract: The present invention relates to cycloalkylpyrimidinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.Type: GrantFiled: April 24, 2006Date of Patent: March 20, 2007Assignee: Merck & Co., Inc.Inventors: Mark E. Fraley, Robert M. Garbaccio
-
Patent number: 7192950Abstract: The invention relates to novel benzazepines and related heterocyclic derivatives (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as orexin receptor antagonists.Type: GrantFiled: December 19, 2001Date of Patent: March 20, 2007Assignee: Actelion Pharmaceuticals, Ltd.Inventors: Hamed Aissaoui, Martine Clozel, Thomas Weller, Ralf Koberstein, Thierry Sifferlen, Walter Fischli
-
Patent number: 7192951Abstract: Combinations of diuretics and vasopressin antagonists are useful to slow and reverse the symptoms and process of congestive heart failure, to increase the excretion of water in the urine, and to decrease the excretion of sodium and potassium ions in urine. Preferred vasopressin antagonists have the formula wherein R and R5 are hydrogen or lower alkyl; R1, R2, and R3 are hydrogen, halo, alkyl, alkoxy, and amino; and R4 is hydrogen or phenyl, and a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 16, 2005Date of Patent: March 20, 2007Assignee: Astellas Pharma Inc.Inventors: Rebecca Guggemos Bakker-Arkema, Milton Lethan Pressler
-
Patent number: 7192952Abstract: The present invention relates to therapeutically active and selective inhibitors of the enzyme DPP-IV of formula I, pharmaceutical compositions comprising the compounds and the use of such compounds for and the manufacture of medicaments for treating diseases that are associated with proteins that are subject to inactivation by DPP-IV, such as type 2 diabetes and obesityType: GrantFiled: March 2, 2005Date of Patent: March 20, 2007Assignee: Novo Nordisk, A/SInventors: Anders Bendtz Kanstrup, Christian Klarner Sams, Jane Marie Lundbeck, Lise Brown Christiansen, Marit Kristiansen
-
Patent number: 7192953Abstract: Compounds of formula (I) have antibacterial activity; wherein Q represents a radical of formula —N(OH)CH(?O) or formula —C(?O)NH(OH); Y represents —C(?O)—, —C(?S)—, —S(?O)—, or —SO2—; R1 represents hydrogen, C1–C6 alkyl or C1–C6 alkyl substituted by one or more halogen atoms, or, except when Q is a radical of formula —N(OH)CH(?O), a hydroxy, C1–C6 alkoxy, C1–C6 alkenyloxy, halogen, amino, C1–C6 alkylamino, or di-(C1–C6 alkyl)amino group; R2 represents a substituted or unsubstituted C1–C6 alkyl, C1–C3 alkyl-O—C1–C3 alkyl, C1–C3 alkyl-S—C1–C3 alkyl, cycloalkyl(C1–C3 alkyl)-, aryl(C1–C3alkyl)-, heterocyclyl(C1–C3 alkyl)-, or R1R2N—C1–C3 alkyl group wherein R1 represents hydrogen or C1–C3 alkyl and R2 represents C1–C3 alkyl, or R1R2N-represents a cyclic amino group; R3 and R4 taken together with the nitrogen atoms to which they are respectively attached form a saturated heterocyclic ring of from 4 to 7 ring atoms, which may be fused to a second carbocyclic or heterocyclic ring, either of which rings may optionallType: GrantFiled: December 1, 2003Date of Patent: March 20, 2007Assignee: Vernalis (Oxford) LimitedInventor: Stephen Peter East
-
Patent number: 7192954Abstract: The present invention is directed to compounds that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.Type: GrantFiled: March 10, 2004Date of Patent: March 20, 2007Assignee: Merck & Co., Inc.Inventors: Ian M. Bell, Cory R. Theberge, Theresa M. Williams, C. Blair Zartman, Xu-Fang Zhang, Steven N. Gallicchio
-
Patent number: 7192955Abstract: Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.Type: GrantFiled: May 2, 2006Date of Patent: March 20, 2007Assignee: Avanir PharmaceuticalsInventors: Federico C. A. Gaeta, Andrew Baird, Jerry Anchin, Wenbin Ying, Robert Florkiewicz, Jagadish Sircar, Sunil Kumar K.C.
-
Patent number: 7192956Abstract: The present invention provides methods of inducing contraception which includes delivering to a female a composition containing a compound of formula I or formula II, or tautomers thereof, in a regimen which involves delivering one or more of a selective estrogen receptor modulator, wherein formula I is: and wherein R1–R5 and Q1 are defined as described herein. Methods of providing hormone replacement therapy and for treating carcinomas, dysfunctional bleeding, uterine leiomyomata, endometriosis, and polycystic ovary syndrome is provided which includes delivering a compound of formula I and a selective estrogen receptor modulator are also described.Type: GrantFiled: June 23, 2003Date of Patent: March 20, 2007Assignee: WyethInventors: Andrew Fensome, Gary S. Grubb, Diane Deborah Harrison, Richard Craig Winneker, Puwen Zhang, Jeffrey Curtis Kern, Eugene Anthony Terefenko
-
Patent number: 7192957Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.Type: GrantFiled: February 24, 2005Date of Patent: March 20, 2007Assignee: Schering CorporationInventors: Srikanth Venkatraman, F. George Njoroge, Melissa L. Blackman, Wanli Wu, Latha G. Nair, Ashok Arasappan, Stephane L. Bogen, Kevin X. Chen, Mousumi Sannigrahi, Frank Bennett, Viyyoor M. Girijavallabhan